I noticed that I didn't post his entire discussion on MannKind.Here's the rest...

TLSR: Nektar Therapeutics (NASDAQ:NKTR) had an inhalable insulin product approved called Exubera (human insulin of recombinant DNA origin) that was marketed for a short period. Its partner was Pfizer Inc. (NYSE:PFE), which returned the product and all rights back to Nektar after marketing the product for less than a year. Could you tell me how Afrezza will be a better product and why it will be more marketable if it is approved?

MH: Lung function tests are very different between the two products, not just in the amount of insulin inhaled but also in the overall metabolic effects that both devices produce. Also, the two drug delivery devices are very different if you look at them. The Exubera device was a tall tube.

TLSR: It looked like a bong.

MH: Yes, you could say that it looked like a big bong that Pfizer was asking the patient to pull out at a restaurant or at home on a daily basis and get comfortable with. Afrezza, with the Dreamboat device, will fit in the palm of your hand. It would look like you’re covering your mouth while coughing, when in fact you are inhaling insulin. Nobody in the room will even know that you just took a dose of insulin. It is a dramatically different product, not just by its optics but also in terms of how it affects the body metabolically.